Andere talen KalVista Pharmaceuticals, Inc.

Aandelen

KALV

US4834971032

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
12,17 ^USD	-0,08%		+16,02%	-0,65%

22/04	Kalvista Pharmaceuticals, Inc. Benoemt William C. Fairey tot lid van de Raad van Bestuur	CI
18/03	KalVista Pharmaceuticals presenteert gegevens uit de praktijk over de last van behandeling en de aanvalsduur van HAE op de 2024 HAEi Regional Conference Americas	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05
KalVista Pharmaceuticals : Corporate Presentation May 2024	02/05
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year	01/05
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors	22/04
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	22/04
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/04
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference	03/04
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18/03
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18/03
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat	13/03
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat	12/03
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	11/03
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update	11/03
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08/03
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen KalVista Pharmaceuticals, Inc.

Aandelen

KALV

US4834971032

Andere talen

Filters